Cannabidinoid derivatives

A compound having the structure of Formula III:

• or a pharmaceutically acceptable salt, or prodrug thereof, wherein:
• X is independently either a C or N;
• R2-R3 are each independently a hydroxyl or (C1-C2)alkoxy;
• R6 is selected from the group consisting of a (C1-C12)alkyl, a hetero(C1-C11)alkyl, a (C1-C12)alkenyl, a -hetero(C1-C11)alkenyl, a (C1-C12)alkynyl, and a hetero(C1-C11)alkynyl;
• R11-R18 are each independently selected from the group consisting of hydrogen, deuterium, FG, optionally substituted (C1-C8)alkyl, optionally substituted hetero(C1-C8)alkyl, optionally substituted (C1-C8)alkenyl, optionally substituted hetero(C1-C8)alkenyl, optionally substituted (C1-C8)alkynyl, optionally substituted hetero(C1-C8)alkynyl;
• and
• R21-R31 are each independently selected from the group consisting of hydrogen, deuterium, FG, optionally substituted (C1-C8)alkyl, hetero(C1-C8)alkyl, optionally substituted (C1-C8)alkenyl, optionally substituted hetero(C1-C8)alkenyl, optionally substituted (C1-C8)alkynyl, optionally substituted hetero(C1-C8)alkynyl, optionally substituted (C5-C8)cycloalkyl, optionally substituted (C5-C8)cycloalkenyl, optionally substituted (C5-C8)cycloalkynyl, optionally substituted (C4-C8)heterocycle, optionally substituted aryl, and optionally substituted extended mixed ring system,
• wherein if X are carbon atoms and the bonds represented by a dash lines are doubly covalent bonds, then at least one of R21-R31 are not hydrogen atoms, thereby affording a substituted aryl group.